In the Journals

Location linked to likelihood of receiving high-cost drugs for advanced lung cancer

December 5, 2019
Patients with a primary diagnosis of metastatic non-small cell lung cancer appeared more likely to receive newer, high-cost antineoplastic agents at…
In the Journals

Levofloxacin reduces febrile episodes, death early in therapy for newly diagnosed myeloma

December 3, 2019
Levofloxacin prophylaxis during the first few months of active myeloma treatment significantly reduced febrile episodes and mortality compared with…
Cover Story

Near the Nation’s Capital Lies a ‘House of Hope’

Cell Therapy Next, November/December 2019
Chimeric antigen receptor T-cell therapies have been approved by the FDA for two indications thus far, with a third for multiple myeloma expected…

Blood-based assays ‘where we are headed’ to guide therapy decisions

November 21, 2019
Tumor mutational burden seems to have arrived at an uncertain juncture in its exploration as a potential biomarker for response to immunotherapy. …

‘Surprising’ link between ibrutinib, hypertension spurs further study

November 19, 2019
Ibrutinib, a paradigm-changing drug for the treatment of various blood cancers, appeared to be more closely associated with new or worsened…

Will the use of PARP inhibitors in advanced ovarian cancer with wild-type BRCA lead to improved OS rates?

HemOnc Today, November 10, 2019
POINT Significant survival benefits can be hidden in the noise of any clinical trial. Part of this is due to the success we’ve had recently in…
Cover Story

PARP inhibitors take big step toward changing practice

HemOnc Today, November 10, 2019
With four FDA-approved agents and several potentially practicing-changing studies presented at medical conferences this year, the role of…

Lymphatic vessels active, anatomical determinants of effective antitumor immunity

November 1, 2019
By Amanda W. Lund, PhD The prevailing model of lymphatic vessel involvement in cancer is that tumor cells use lymphatic vessels as passive escape…

NCCN’s off-label cancer treatment recommendations ‘constitute a problem’

October 29, 2019
Many novel, costly and toxic cancer therapies continue to be broadly recommended for off-label use by the National Comprehensive Cancer Network based…

Study suggests NCCN off-label recommendations valid based on available evidence

October 29, 2019
Although National Comprehensive Cancer Network guidelines frequently recommend use of drugs in settings beyond their FDA-approved indications, the…